Lumiradx Stock Current Valuation
Valuation analysis of LumiraDx helps investors to measure LumiraDx's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
LumiraDx Company Current Valuation Analysis
LumiraDx's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current LumiraDx Current Valuation | 440.16 M |
Most of LumiraDx's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LumiraDx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, LumiraDx has a Current Valuation of 440.16 M. This is 96.94% lower than that of the Biotechnology sector and 94.35% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.35% higher than that of the company.
LumiraDx Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LumiraDx's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LumiraDx could also be used in its relative valuation, which is a method of valuing LumiraDx by comparing valuation metrics of similar companies.LumiraDx is currently under evaluation in current valuation category among its peers.
LumiraDx Fundamentals
| Return On Equity | -15.64 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (2.67) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 440.16 M | |||
| Shares Outstanding | 161.02 M | |||
| Shares Owned By Insiders | 55.41 % | |||
| Shares Owned By Institutions | 25.26 % | |||
| Number Of Shares Shorted | 1.43 M | |||
| Price To Earning | 13.70 X | |||
| Price To Book | 18.28 X | |||
| Price To Sales | 1.97 X | |||
| Revenue | 254.48 M | |||
| Gross Profit | 61.02 M | |||
| EBITDA | (273.54 M) | |||
| Net Income | (449.19 M) | |||
| Cash And Equivalents | 106.45 M | |||
| Cash Per Share | 0.42 X | |||
| Total Debt | 401.25 M | |||
| Current Ratio | 2.76 X | |||
| Book Value Per Share | (0.67) X | |||
| Cash Flow From Operations | (162.11 M) | |||
| Short Ratio | 0.09 X | |||
| Earnings Per Share | (1.08) X | |||
| Target Price | 0.65 | |||
| Number Of Employees | 1.21 K | |||
| Beta | 1.71 | |||
| Market Capitalization | 249.63 M | |||
| Total Asset | 441.01 M | |||
| Retained Earnings | (1.09 B) | |||
| Working Capital | 179.82 M | |||
| Net Asset | 441.01 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |